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Abstract
AIM
To develop a scale of domains associated with the 
health-related quality-of-life (HRQOL) in patients with 
cirrhosis-related ascites.
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METHODS
We initially undertook literature searches and a quali-
tative study in order to design a cirrhosis-associated 
ascites symptom (CAS) scale describing symptoms 
with a potential detrimental impact on health related 
quality of life (HRQL) (the higher the score, the worse 
the symptoms). Discriminatory validity was assessed 
in a validation cohort including cirrhotic patients with 
(1) tense/severe; (2) moderate/mild; or (3) no ascites 
(controls). Patients also completed chronic liver disease 
questionnaire (CLDQ) and the EuroQoL 5-Dimensions 
5-Level (EQ-5D-5L) questionnaire evaluating HRQL. 
The relation between scale scores was analysed using 
Spearman correlations. 
RESULTS
The final CAS scale included 14 items. The equivalent 
reliability was high (Chronbach’s alpha 0.88). The 
validation cohort included 103 patients (72% men, 
mean age 62.4 years). The mean scores for each 
question in the CAS scale were higher for patients 
with severe/tense ascites than for mild/moderate 
ascites and controls. Compared with controls (mean 
= 9.9 points), the total CAS scale score was higher for 
severe/tense ascites (mean = 23.8 points) as well as 
moderate/mild ascites (mean = 18.6 points) (P  < 0.001 
both groups). We found a strong correlation between 
the total CAS and CLDQ score (rho = 0.82, P  < 0.001) 
and a moderate correlation between the CAS and the 
EQ-5D-5L score (0.67, P  < 0.001). 
CONCLUSION
The CAS is a valid tool, which reflects HRQOL in patients 
with ascites. 
Key words: Health-related quality-of-life; Cirrhosis; 
Symptom burden; Symptom assessment
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This paper presents a newly generated 
cirrhosis-associated ascites symptom scale consisting of 
14 items. The questionnaire addresses relevant questions 
of symptom burden of cirrhosis-associated ascites, takes 
only five minutes to complete and correlates strongly 
with chronic liver disease questionnaire score in patients 
with cirrhosis and ascites.
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INTRODUCTION
Ascites is a serious complication to cirrhosis[1,2]. Without 
liver transplantation, only about 55% of patients with 
cirrhosis and ascites are alive, five years after the 
initial diagnosis. In addition, the severity of symptoms 
associated with ascites may have a detrimental impact 
on health-related quality of life (HRQL). Five previous 
studies have evaluated the HRQL in patients with 
cirrhosis using generic questionnaires including the 
Medical Outcome Study Short Form 36 (SF-36), the 
Nottingham Health Profile and the Sickness Impact 
Profile[3-7]. All studies found that cirrhosis is associated 
with a detrimental effect on HRQL. None of the studies 
were designed to evaluate the association between 
ascites severity and the quality of life. However, 
one study found that disease progression, including 
development of ascites, is associated with an impaired 
HRQL[7]. Disease-specific questionnaires developed for 
the assessment of HRQL in patients with liver disease 
and cirrhosis have reached similar conclusions[8,9]. The 
questionnaires include aspects that are of particular 
relevance to patients with cirrhosis, such as concerns 
about complications and liver transplantation. The 29 
item chronic liver disease questionnaire (CLDQ) was 
used to evaluate HRQL in 204 patients representing all 
stages of various liver diseases[10]. The scale correlates 
with the severity of the underlying liver disease and 
is also associated with active medical and psychiatric 
comorbidity. Liver failure, development of minimal 
hepatic encephalopathy, malnutrition, abdominal pain, 
fatigue, and anxiety may also affect HRQL[11,12]. 
None of previous studies specifically evaluated the 
association between the severity of ascites related 
symptoms and HRQL. However, it is likely that the 
severity of symptoms is important.
In clinical trials of medical interventions, HRQL as 
well as symptom management are important para-
meters in the assessment of intervention benefits and 
harms[4,5,13,14]. A study including 212 outpatients with 
cirrhosis found that the management of cirrhosis-related 
complications is associated with improved HRQOL 
assessed using the Medical Outcomes Study Form, SF-36 
and CLDQ questionnaires. The study found that ascites 
as well as a decrease in haemoglobin and previous 
hepatic encephalopathy predicted the HRQOL[15].
We therefore developed and evaluated the predictive 
ability of a scale specifically made to assess symptoms 
related to cirhosis-associated ascites. We subsequently 
undertook a multicenter cohort study to evaluate the 
association between our scale and a disease specific 
scale (CLDQ) as well as a generic HRQL questionnaire 
(EQ-5D-5L). 
MATERIALS AND METHODS
The present study was conducted as a multi-center 
study, with participation of three university hospitals in 
Denmark: Copenhagen University Hospital Hvidovre, 
Odense University Hospital and Aarhus University Hospital. 
The study was approved by the Danish Data protection 
Agency, journal no: 04054, ID: AHH-2015-075. 
The development of the cirrhosis-associated ascites 
symptom (CAS) scale included a literature review and a 
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qualitative study to evaluate face and content validity as 
well as discriminatory ability. 
We initially searched for previously validated scales 
in MEDLINE and EMBASE (‘ascites’ AND (‘quality of life 
[Mesh]’ OR ‘life quality’ OR ‘health-related quality of 
life’ OR ‘health related quality of life’ OR ‘symptoms’) 
AND (‘cirrhosis’ OR ‘end-stage liver disease’). The 
searches were combined with manual searches of 
reference lists in potentially relevant articles and 
conference proceedings. None of our searches identified 
questionnaires evaluating symptoms associated with 
ascites. 
We then proceeded with a qualitative study. Ini-
tially, the study group and ten independent experts 
identified and listed what they believed were the 
most important symptoms with an expected negative 
impact on HRQL (six hepatologists and four nurses with 
clinical experience in the management of patients with 
ascites from Gastro Unit, medical division, Copenhagen 
University Hospital Hvidovre, were interviewed). In 
our selection of symptoms (domains), we decided that 
they should occur frequently or be severe enough to 
have substantial impact on daily function in order to be 
considered for our scale. 
After the selection of domains, we first conducted 
open interviews followed by structured interviews of 
ten patients with cirrhosis and moderate (n = 4) or 
severe ascites (n = 6). The interviews took place in a 
quiet room in the hospital ward. The selected domains 
were initially presented and patients were asked to 
rate them (Supplementary Table 1) according to the 
patient’s perceived ‘importance’, on the extent to which 
the symptom had bothered them. Each patient was 
then asked to complete the preliminary questionnaire 
themselves and to answer a debriefing form with the 
questions: (1) How long did it take to complete the 
questionnaire? (2) Did you need assistance from others 
to fill out the questionnaire? (3) Did you find any items 
confusing or difficult to respond to (and if so, list the 
items)? (4) Did you find any items upsetting? (5) Were 
any important items missing? and (6) Do you have any 
additional comments? 
We revised the questionnaire instrument based 
on the answers. One question, which patients found 
upsetting and two questions, which patients found to 
be irrelevant or unimportant were removed. Revisions 
were decided by consensus among investigators. 
Validation of the CAS scale (known group comparison)
After the development of the questionnaire, we 
prospectively enrolled a validation cohort (known group 
comparison) consisting of patients with cirrhosis of 
any aetiology and (1) severe/tense ascites; (2) mild/
moderate ascites; and (3) no ascites as determined 
through a combination of clinical assessments and 
abdominal ultrasound. All gave their informed consent to 
participate. Subjects were attending out-patient clinics 
or were admitted to hospital ward with ascites as their 
1652 April 21, 2018|Volume 24|Issue 15|WJG|www.wjgnet.com
Please answer the following questions with a cross or tick with regards to how you have felt in the past four weeks.
Nej Sjældent Indimellem Ofte
No Rarely Sometimes Often
1 Har du ondt i maven? 
Do you have stomach ache? 
2 Har du ømhed i maven?
Does your stomach feel sore?
3 Har du kvalme?
Do you feel nauseous?
4 Har du madlede?
Do you feel an aversion for food?
5 Har du nedsat appetit?
Do you experience a loss of appetite?
6 Har du ændret afføring?
Have you experienced a change in your stool?
7 Har du følt dig utilpas?
Have you felt uncomfortable?
8 Er du træt?
Are you tired?
9 Har du åndenød?
Do you experience a shortness of breath?
10 Har du svært ved at trække vejret helt igennem?
Do you feel troubled when breathing deeply?
11 Har du svært ved at få tøj eller sko på?
Are you disabled when dressing or putting on shoes?
12 Har du svært ved at komme rundt derhjemme?
Do you experience difficulties in mobility at home?
13 Har du svært ved at gå?
Do you experience trouble walking?
14 Har du ondt i benene?
Do your legs hurt?
Table 1  Cirrhosis-associated ascites symptom scale in Danish
Riedel AN et al . Development and predictive validity of the CAS scale
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alpha was 0.88 for the total score, which we considered 
as acceptable. The validation cohort included 103 
patients. 
Demographic data are stated in Table 2. Seventy-
four were male (72%) and mean age was 62.4 years 
(range 38-85). The proportion of patients with Child 
Pugh A was 24%, Child Pugh B: 58% and Child Pugh C: 
19%. Forty-four percent had severe/tense ascites and 
27% had mild/moderate ascites. A control group of 31 
patients (30%) had no ascites. 
Discriminant validity
The mean scores for each question in the CAS scale 
suggested that symptoms were worse for patients with 
severe/tense ascites than for controls (Figure 1).
Symptoms also appeared worse for patients with 
mild/moderate ascites. Accordingly, the CAS scale 
score found that patients with severe/tense ascites or 
moderate/mild ascites had significantly worse scores 
compared with controls (P < 0.001 and P < 0.001; 
Figure 2). 
As expected, patients with severe/tense ascites 
had the worst symptoms scores. Based on the CLDQ 
questionnaire, tense/severe ascites had a detrimental 
impact on HRQOL compared with controls (P < 0.001) 
as did moderate/mild ascites (P = 0.002). The EQ-5D-
5L also found a lower HRQOL in patients with severe/
tense ascites (P = 0.002) or moderate/mild ascites (P 
= 0.038). 
Convergent validity
We found a strong correlation between the CAS and 
the CLDQ total score (Spearman’s rho = 0.82, P < 
0.001) as well as the CLDQ subscores; fatigue (0.78, 
P < 0.001), activity (0.81, P < 0.001) and systemic 
primary problem. Subjects with hepatic encephalopathy 
or other cognitive disability were excluded.
Subjects completed the following scales and qu-
estionnaires: (1) CAS scale; (2) Chronic Liver Disease 
Questionnaire[9]; and (3) EQ-5D-5L questionnaire[16,17]. 
Statistical analysis 
Statistics were calculated using STATA IC v14 R2 and 
GraphPad Prism v6. We used the Crohnbach’s alpha to 
assess equivalent reliability. We defined discriminant 
validity as the ability of the questionnaire to discriminate 
between the severity of ascites. Discriminant validity 
was evaluated using Dunnett’s test to adjust for multi-
ple comparisons. The severe and mild ascites groups 
(assuming that this group has fewer and less severe 
symptoms than patients with severe ascites) were 
compared with the control group and P-values < 0.05 
were considered significant. We originally planned to 
evaluate convergent validity with previously validated 
scales assessing symptoms or HRQOL associated with 
ascites. Since no previous scales were identified, we 
used the CLDQ and the EQ-5D-5L. We compared scale 
scores using Spearman correlation and included the (1) 
CAS scale; (2) CLDQ; (3) CLDQ subscale parameters; 
and (4) EQ-5D-5L. The CLDQ subscale parameters 
are defined domains consisting of specific questions 
in the CLDQ questionnaire. These domains include 
fatigue, emotional function, worry, activity, abdominal 
symptoms and systemic symptoms[9].
Correlations higher than 0.70 were considered 
strong and values below 0.40 were interpreted as poor. 
RESULTS
The final scale included 14 items (Table 1). Chronbach’s 
There were no patients in Child Pugh Class A with tense ascites.
Table 2  Patient characteristics according to degree of ascites n  (%)
Control group, no ascites (n  = 31) Mild/moderate (n  = 27) Tense (n  = 45) Total (n  = 103)
Age: mean (SD)       61.5 (8.4)         62.3 (10.2)         63.1 (11.3)         62.4 (10.1)
Gender: Males   23 (74)   19 (70)   32 (71)   74 (72)
Etiology 
   Alcohol   28 (90)   22 (81)   38 (86)   88 (86)
   Viral   1 (3)   2 (7)   3 (7)   6 (6)
   Alcohol and viral   1 (3)   1 (4)   3 (7)   5 (5)
   Other     3 (10)     4 (15)     6 (13)   13 (13)
MELD score: mean (SD)       10.1 (3.3)       14.8 (6.2)       15.9 (6.3)       13.8 (6.0)
Child PUGH: mean (SD)   6.2 (1.8)         8.1 (1.3)         9.1 (1.4)         7.9 (1.9)
   Class A   19 (61)     4 (15) -   23 (22)
   Class B     7 (23)   17 (63)   27 (60)   51 (50)
   Class C   2 (6)   2 (7)   12 (27)   16 (16)
Laboratory values (SD)
   Hemoglobin (mmol/L)         8.4 (1.4)         7.1 (1.2)         6.4 (1.4)         7.2 (1.6)
   White blood cells (× 109/L)         6.9 (2.6)         7.2 (3.9)         7.3 (3.5)         7.1 (3.3)
   Platelets (mmol/L) 145 (65) 158 (95) 160 (87) 155 (83)
   Albumin (g/L)    35 (5.8)    29 (5.9)   30 (14)   31 (10)
   Cogulation factor Ⅱ, Ⅶ, Ⅹ (INR)         1.3 (0.3)         1.4 (0.3)         1.5 (0.5)         1.4 (0.4)
   Creatinine (μmol/L)   74 (17)   87 (29)   94 (48)   86 (37)
   Sodium (mmol/L)  138 (3.6)  134 (5.9)  132 (6.9)  135 (6.3)
   Potassium (mmol/L)         4.1 (0.4)         4.3 (0.5)         4.2 (0.7)         4.2 (0.6)
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symptoms (0.77, P < 0.001) (Table 3). The CAS 
correlation with the generic scale (EQ-5D-5L) was 
moderate (0.67, P < 0.001). 
DISCUSSION
We found that the developed CAS scale is effective 
in discriminating between various severities of 
ascites. It takes five minutes to perform and is easily 
implemented in daily practice. Moreover the CAS 
scale correlates strongly with the well-developed 
liver disease-specific HRQL instrument, CLDQ[9]. This 
suggests that our symptom assessment scale reflects 
the perceived HRQL of patients with cirrhosis and 
ascites. The CLDQ subparameters: fatigue, activity and 
systemic symptoms were likewise strongly correlated 
with the CAS scale suggesting that these domains 
are influential symptoms or functional limitations for 
patient with ascites. Surprisingly, the subparameter 
abdominal symptoms was not associated with the CAS 
scale. This may be due to use of words or inaccuracy 
of the questions, and will need further investigations 
for clarification. The total CLDQ was better correlated 
with CAS than each subparameter. This may be due 
to the impact of low quality of life affecting all aspects 
of life, allowing a total low score higher statistical 
significance. The CAS versus EQ-5D-5L correlation was 
moderate. The EQ-5D-5L is a generic scale which aims 
at examining non-disease specific HRQL[16,18,19], and 
specific symptoms related to cirrhosis and ascites may 
be undetected by this questionnaire. On the contrary, 
the CLDQ is created for patients with chronic liver 
disease, and it includes questions concerning ascites 
related symptoms and gains a stronger correlation with 
the CAS score.
To our knowledge, no previous study has developed 
and validated a questionnaire specifically aimed at 
evaluating HRQL in patients with ascites. However, 
previous literature describes correlations between 
disease severity in chronic liver disease and HRQL[7,12,20]. 
One study found that ascites had significant effects on 
self-related disease progression in cirrhosis[7]. Another 
showed that ascites was not a predictor for HRQL[12] 
and two studies found that management of ascites may 
improve HRQL[15,21]. In a study evaluating the impact 
of the Medical Outcomes Study Short Form (SF-36) 
on HRQL in 523 patients with cirrhosis and ascites, a 
strong association between the physical component 
score (PCS) and leg edema, history of previous hepatic 
encephalopathy, severe ascites and low serum sodium 
levels were found[22]. The PCS includes questions on 
physical role, physical functioning, and body pain and 
general health. Also, a lower mental component score 
in the SF-36 was associated with low levels of serum 
sodium and treatment with lactulose. Hence, several 
factors influence HRQL when measured by SF36 and 
the impact of ascites was not clearly established by this 
study.
The CAS score comprises only 14 questions with 
high compliance to answering, takes only five minutes 
to complete and is readily implemented in daily clinic. 
The present study supports the results implying corre-
lation between ascites severity and HRQL assuming 
that the CAS scale is valid and reliable. Progression in 
liver disease (e.g., measured by Child Pugh score which 
includes presence of ascites) is associated with ascites 
severity grade. This argues that our results support 
previous literature finding a correlation between liver 
disease severity and HRQL. 
Our study has some considerable weaknesses. 
The relatively small sample size is one of the main 
limitations. Moreover, the majority of patients had 
cirrhosis due to alcohol. Dependency of alcohol, 
concomitant diseases related to alcohol use or cirrhosis 
that may impact physical health was not assessed in our 
cohort. Malnutrition is a serious complication to cirrhosis 
with impact on HRQL[23]. Also, impact of socioeconomic 
factors may influence quality of life substantially[24,25]. 
Future studies may address the synergy between various 
factors affecting quality of life in cirrhosis and ascites. 
The CAS scale is a specific scale evaluating the impact 
of symptoms related to ascites. When assessing overall 
quality of life on chronic liver disease or the impact of 
Table 3  Correlation between cirrhosis-associated ascites 
symptom score, EuroQoL 5-Dimensions 5-Level scale 
questionnaire and chronic liver disease questionnaire total 
score and subscores
Rho P  value
Total EQ-5D-5L -0.67 < 0.001
Total CLDQ score -0.821 < 0.001
   Fatigue -0.781 < 0.001
   Emotional function -0.55 < 0.001
   Worry -0.47 < 0.001
   Abdominal symptoms -0.66 < 0.001
   Activity -0.811 < 0.001
   Systemic symptoms -0.771 < 0.001
1Strong correlations. CLDQ: Chronic liver disease questionnaire; EQ-5D-
5L: EuroQoL 5-Dimensions 5-Level scale questionnaire.
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Figure 1  Mean cirrhosis-associated ascites symptom scores by question 
number and ascites severity. 
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multi-morbidity in cirrhosis; validated and recommended 
scores such as SF36 or CLDQ should be used, with the 
CAS scale as a supplement[9]. Consequently, CAS scale 
validation also requires further research on larger sample 
size and applied on standardized groups of subjects. An 
interesting study setup would be to test the CAS scale 
on patients with cirrhosis presented with ascites before 
and after treatment. Further, the CAS scale ought to be 
tested as a monitoring tool for efficacy in intervention 
trials, compared with CLDQ and SF-36 questionnaires. 
In conclusion, the present construction and validation 
of the CAS scale seems promising for future research in 
the area of ascites symptom management and HRQL. 
Initially the scale requires testing in other study setups 
in order to clarify the quality and practicability of the 
questionnaire. In future perspectives an optimized 
and/or further validated version of the CAS scale can 
be used as a monitoring tool in interventional trials 
and to assess the effects of standardized treatment. 
Ultimately the CAS scale can contribute to gaining 
further knowledge on how to treat ascites effectively 
and consequently improve patients’ quality of life.
ARTICLE HIGHLIGHTS
Research background
Cirrhosis is associated with a detrimental effect on health related quality 
of life (HRQL). Disease-specific questionnaires have been developed for 
the assessment of HRQL in patients with liver disease and cirrhosis. The 
questionnaires include aspects that are of particular relevance to patients with 
cirrhosis, such as concerns about complications and liver transplantation. 
Research motivation
No previous studies have specifically evaluated the association between the 
severity of ascites related symptoms and HRQL. However, it is likely that the 
severity of symptoms is important.
Research objectives 
We therefore developed and evaluated the predictive ability of a symptom 
assessment scale specifically made to assess symptoms related to cirhosis-
associated ascites. We subsequently undertook a multicenter cohort study to 
evaluate the association between our scale and a disease specific scale (CLDQ) 
as well as a generic HRQL questionnaire (EQ-5D-5L).
Research methods
Development of the cirrhosis-associated ascites symptom (CAS) scale included 
a literature review, and a qualitative study to evaluate face and content 
validity as well as discriminatory ability. We initially searched for previously 
validated scales in MEDLINE and EMBASE. The searches were combined 
with manual searches of reference lists in potentially relevant articles and 
conference proceedings. We then proceeded with a qualitative study, where 
ten independent experts identified and listed what they believed were the most 
important symptoms with an expected negative impact on HRQL. Symptoms 
should occur frequently or be severe enough to have substantial impact on 
daily function in order to be considered for our scale. 
We then conducted open interviews followed by structured interviews of 
ten patients with cirrhosis and moderate (n = 4) or severe ascites (n = 6). The 
selected domains were initially presented and patients were asked to rate them 
according to the patient’s perceived ‘importance’, on the extent to which the 
symptom had bothered them. 
We revised the questionnaire instrument based on the answers. 
After the development of the questionnaire, we prospectively enrolled 
a validation cohort consisting of patients with cirrhosis of any aetiology and 
severe, moderate or no ascites. All gave their informed consent to participate. 
Subjects completed the following scales and questionnaires: CAS scale; 
Chronic Liver Disease Questionnaire; and EQ-5D-5L questionnaire. 
We used the Crohnbach’s alpha to assess equivalent reliability. 
Discriminant validity was evaluated using Dunnett’s test to adjust for multiple 
comparisons. We originally planned to evaluate convergent validity with 
previously validated scales assessing symptoms or HRQOL associated with 
ascites. Since no previous scales were identified, we used the CLDQ and 
the EQ-5D-5L. We compared scale scores using Spearman correlation and 
included the CAS scale, CLDQ, CLDQ subscale parameters, and EQ-5D-5L. 
Correlations higher than 0.70 were considered strong and values below 0.40 
were interpreted as poor. 
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Figure 2  Median test scores with SEM divided by control, mild/moderate 
and tense ascites respectively. A: CAS scale. Control vs mild/moderate, P < 
0.001; control vs tense, P < 0.001; B: CLDQ. Control vs mild/moderate P = 0.002; 
Control vs tense, P < 0.001; C: EQ-5D-5L. Control vs mild/moderate, P = 0.038; 
Control vs tense, P = 0.002. CAS: Cirrhosis-associated ascites symptom scale; 
CLDQ: Chronic liver disease questionnaire; EQ-5D-5L: EuroQoL 5-Dimensions 
5-Level scale questionnaire.
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Research results
The final scale included 14 items. Chronbach’s alpha was 0.88 for the total 
score, which we considered as acceptable. The validation cohort included 103 
patients. 
The proportion of patients with Child Pugh A was 24%, Child Pugh B: 58% 
and Child Pugh C: 19%. Fourty-four percent had severe ascites and 27 percent 
had moderate ascites. A control group of 30 percent had no ascites. The mean 
scores for each question in the CAS scale suggested that symptoms were 
worse for patients with severe ascites than for controls. The CAS scale score 
found that patients with severe ascites or moderate ascites had significantly 
worse scores compared with controls. Based on the CLDQ questionnaire, 
severe ascites had a detrimental impact on HRQOL compared with controls 
as did moderate ascites. The EQ-5D-5L also found a lower HRQOL in patients 
with severe or moderate ascites. We found a strong correlation between the 
CAS and the CLDQ total score as well as the CLDQ subscores; fatigue, activity 
and systemic symptoms. 
Research conclusions
This study has developed and tested a symptom assessment scale for the 
impact of ascites in cirrhosis. The CAS scale is easy to use and correlates well 
with more extensive QoL questionnaires. 
Research perspectives
This study has brought focus to the impact and importance of effective 
management of ascites in chronic liver disease. 
The CAS scale should be tested in larger clinical and interventional trials, 
preferably in combination with CLDQ or other generic health related quality of 
life questionnaires.
The CAS scale should be tested in larger cohorts with various etiologies 
for chronic liver disease and ascites, also in malignant ascites. The CAS scale 
should also be tested in interventional trials in which the effect of a given 
intervention on the CAS scale is evaluated, to demonstrate whether the CAS 
scale is applicable as a monitoring tool in ascites. 
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